ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,473.17
      -0.25%
      US Tech 100
      19,288.80
      -0.62%
      Dow Jones
      39,134.76
      0.77%
      Brent Oil
      84.94
      -0.08%
      Bitcoin
      64,628.45
      -0.30%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. OSE Immunotherapeutics (OSE) Quote

      OSE Immunotherapeutics

      OSE Immunotherapeutics (OSE)

      EU
      6.31
      0.46
      (7.86%)
      Closed June 21 11:30AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      6.31
      Bid
      6.30
      Ask
      6.39
      Volume
      299,420
      5.94 Day's Range 6.45
      2.705 52 Week Range 8.63
      Market Cap
      136.618M
      Previous Close
      5.85
      Open
      5.96
      Last Trade
      494
      @
      6.31
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      204,130
      Shares Outstanding
      21,651,101
      Dividend Yield
      -
      PE Ratio
      -5.94
      Earnings Per Share (EPS)
      -1.06
      Revenue
      2.23M
      Net Profit
      -23M

      About OSE Immunotherapeutics

      Sector
      Coml Physical, Biologcl Resh
      Industry
      Coml Physical, Biologcl Resh
      Website
      www.ose-immuno.com
      Headquarters
      Nantes, Loire-atlantique, Fra
      Founded
      1970
      OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 5.85 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 2.705 € to 8.63 €.

      OSE Immunotherapeutics currently has 21,651,101 shares outstanding. The market capitalization of OSE Immunotherapeutics is 136.62 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -5.94.

      OSE Latest News

      More News

      OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)

      OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San...

      24 hours ago
      GlobeNewswire Inc.

      OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société

      OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société OSE...

      June 19 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

      OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth Nantes, France – June 19, 2024...

      June 19 2024
      GlobeNewswire Inc.

      Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules

      Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules Webinaire KOL...

      June 12 2024
      GlobeNewswire Inc.

      OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale

      OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale...

      June 05 2024
      GlobeNewswire Inc.

      Informations relatives au nombre total de droits de vote et d’actions composant le capital

      Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes...

      June 04 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la Société

      OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la Société OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance...

      May 30 2024
      GlobeNewswire Inc.

      Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024

      Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024 Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024...

      May 29 2024
      GlobeNewswire Inc.

      OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques

      OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et...

      May 22 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.94-12.96551724147.257.285.712694616.30703523DE
      4-1.97-23.79227053148.288.595.712033937.29345499DE
      121.45529.96910401654.8558.634.5052041306.6709292DE
      262.2555.41871921184.068.633.1151528595.84896278DE
      522.77578.50070721363.5358.632.7051751165.23764146DE
      156-5.15-44.938917975611.4613.682.705890916.26733308DE
      2602.774.79224376733.6115.82.705823477.22361517DE

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      GRDIGRIID Infrastructure Inc
      $ 1.11
      (98.21%)
      		155.65M
      ZAPPZapp Electric Vehicles Group Ltd
      $ 2.33
      (71.32%)
      		91.49M
      MGOLMGO Global Inc
      $ 0.725
      (58.16%)
      		160.27M
      RELIReliance Global Group Inc
      $ 0.61
      (55.97%)
      		139.38M
      HAOHaoxi Health Technology Ltd
      $ 6.36
      (38.26%)
      		693.26k
      WHLRWheeler Real Estate Investment Trust Inc
      $ 2.75
      (-82.51%)
      		164.01k
      KAVLKaival Brands Innovations Group Inc
      $ 2.90
      (-35.56%)
      		1.31M
      MBIOMustang Bio Inc
      $ 0.5605
      (-34.07%)
      		38.18M
      SONNSonnet BioTherapeutics Holdings Inc
      $ 1.04
      (-32.03%)
      		432.19k
      NKLANikola Corporation
      $ 0.3279
      (-31.82%)
      		269.83M
      NVDANVIDIA Corporation
      $ 130.78
      (-3.54%)
      		518.09M
      NKLANikola Corporation
      $ 0.3279
      (-31.82%)
      		269.83M
      SMXSMX Security Matters Public Company
      $ 0.16
      (34.45%)
      		177.78M
      SQQQProShares UltraPro Short QQQ
      $ 8.32
      (2.46%)
      		166.97M
      MGOLMGO Global Inc
      $ 0.725
      (58.16%)
      		160.27M

      Discussion

      View Full Feed
      XMaster2023 XMaster2023 6 minutes ago
      You are only thinking of 2 events that impact SP. Fortunately, there are many more. The story begins once upon Approval…
      NWBO
      arizona1 arizona1 7 minutes ago
      Check this out! 😍

      https://x.com/TheTennisLetter/status/1803480756515381593
      kabunushi kabunushi 7 minutes ago
      I agree but we have far too little visibility into what NW is doing. First and foremost they need a lot more money to go forward properly, at the least. Both with more ph 3 trials and also with a commercial rollout. I'm afraid it's become very clear that they are not likely to get instant stock mark
      NWBO
      Jimmy Joe Jimmy Joe 7 minutes ago
      Exercise is very expensive.

      Not at Planet Fitness..... cheap. Can join for the price of a Punkin Spice Lotte.
      Just saying.........
      GME
      fuagf fuagf 9 minutes ago
      Sure does. It was a real rational read. Real world experience, clearly, concisely put.
      236T568 236T568 9 minutes ago
      Yep.
      JusticeWillWin JusticeWillWin 9 minutes ago
      Again > 60k at the close...
      COOP
      reaper247 reaper247 12 minutes ago
      Nope hilo,

      Some are just losers lashing out at others for their own poor decisions.

      LOL, IMO and FWIW.
      GVSI
      Wise Man Wise Man 12 minutes ago
      The Net Worth isn't capital to absorb losses.
      Net Worth or Equity isn't a line item or account that you can debit losses from. It's an aggregated amount of its components. A sum.
      Only the Retained Earnings account absorbs the future losses that will come from the quarterly Income State
      FNMA
      Jimmy Joe Jimmy Joe 14 minutes ago
      Got in late tonight. Margin calling....... sounds good to me.

      https://investorshub.advfn.com/uimage/uploads/2024/6/21/dtquldownload.jpg

      Another board I counted 8 massive bubbles approaching the market in general. Am sure I left a few out.
      GME
      tredenwater2 tredenwater2 16 minutes ago
      HUH???? There is no vaccine involved and there are no safety risks apparently.

      More of a moral dilemma. They, like many other pharmas, pushed a vaccine by that they knew was unsafe. They actually had data showing birthrate drops in women, loss of babies, and among other things heart i
      AVXL
      kabunushi kabunushi 16 minutes ago
      Just take the time to read his posts. I don't think he was creating a fake 'long' backstory. I think longs should not jump to conclusions that anybody who posts in a not always rah rah way is short. We gotta ignore the trash talking permabears but not throw out the baby with the bathwater so to spea
      NWBO
      janice shell janice shell 17 minutes ago
      Will he dare go with "Biden Crime Family"?
      Mac-A-Million Mac-A-Million 18 minutes ago
      I remember hearing that as well when they were still in business.....things change when you have been sitting in the Grey Market for a year. Seeing is believing.....I have some decent shares here. .03c would be killer for me.....just saying....$$$$$$!
      CNNA
      janice shell janice shell 19 minutes ago
      Ahem! That would be "Stollen". And we're leaving off all the capital letters.
      kabunushi kabunushi 20 minutes ago
      I appreciate the feedback very much. You are right - I'm very afraid that being patient might mean a more-years long wait for the kind of market cap that this treatment ought to be worth. I'm not concerned with making any other longs nervous. If they are not nervous then maybe there is something wro
      NWBO
      MightyX MightyX 21 minutes ago
      Excellent update..looking fantastic: https://www.linkedin.com/posts/matthias-aydt-aa67bb26_over-the-past-18-months-faradayfuture-has-activity-7209748739459043328-gjm0?utm_source=share&utm_medium=member_android
      FFIE
      HippyTrades HippyTrades 21 minutes ago
      I knew you couldn't Lou
      AXXA
      Stockman1010101 Stockman1010101 24 minutes ago
      Don't hold your breadth for life CHANGING money. Just be thankful if you can double your investment and make sure to push the SELL button because many hear don't know how to use it to give themselves bonuses for struggling with these GME shares.
      GME
      pineyhill pineyhill 27 minutes ago
      Well then Sell and Be Gone.
      LWLG
      Alpha611 Alpha611 30 minutes ago
      Blind mans gold. ... lol
      MOBILEUSD

      Your Recent History

      EU
      OSE
      OSE Immunotherapeutics
      Delayed Upgrade Clock